BSD Medical Obtains Patent License for Primary Breast Cancer Treatment System from Duke University
One of BSD Medical's areas of focus is breast cancer (the number onecancer contracted by women), and BSD has been rapidly expanding the breadth ofits technologies for breast cancer treatment. In June 2007 BSD Medicalreported that it had filed a patent for a new phased array breast treatmentapplicator developed to selectively heat primary breast cancer tumors with theBSD-500 hyperthermia system. This pending patent and the new license withDuke University are mutually inclusive as part of BSD Medical's advancingtechnology to treat primary cancers of the breast.
Earlier this year BSD Medical also introduced a 24 spiral microwaveapplicator that is compatible with its FDA approved BSD-500 hyperthermiasystem, designed to provide large superficial treatment fields applicable totreating advanced chest wall cancers. An initial 24 spiral applicator waspurchased for applications testing at the University of Erlangen in Germany.Concurrently an 8 spiral array applicator developed by BSD Medical has alsobeen purchased and is also being used at the University of Erlangen. Thisapplicator, which is also compatible with the BSD-500 system, allows theoperator separate control of the temperature and power levels in differentzones within the tumor.
A new applicator for treatment of advanced primary breast cancer using theBSD-2000/3D/MR has, in addition, been purchased and is installed at theUniversity of Munich. This applicator utilizes special phased array methodsfor treating the breast. The integration of MR imaging during hyperthermiatreatments of breast tumors, as provided by the BSD-2000/3D/MR, offers newpotential for treatment options of advanced primary breast tumor patients.
Interest in treating beast cancer with hyperthermia therapy received asignificant boost when the Journal of Clinical Oncology published the resultsof a randomized, phase III study conducted at Duke University treatingsuperficial tumors, including recurrent breast tumors, with radiation alonevs. radiation plus hyperthermia therapy. Previously irradiated patients hadthe greatest incremental gain in complete response: 23.5% in the groupreceiving radiation alone vs. 68.2% in the group receiving hyperthermia plusradiation. (See Jones, et. al., JCO Vol. 23, No 13, May 1, 2005.)
BSD Medical Corp. is the leading developer of systems used to deliverhyperthermia therapy for the treatment of cancer. Hyperthermia therapy is usedto kill cancer directly with heat and increase the effectiveness of companionradiation treatments. Research has also shown promising results from the useof hyperthermia therapy in combination with chemotherapy. For furtherinformation visit BSD Medical's website at www.BSDMedical.com or BSD's patientwebsite at www.treatwithheat.com.
Statements contained in this press release that are not historical factsare forward-looking statements, as defined in the Private SecuritiesLitigation Reform Act of 1995. All forward-looking statements are subject torisks and uncertainties detailed in the Company's filings with the Securitiesand Exchange Commission.
SOURCE BSD Medical Corp.
You May Also Like